

HR 1720

COVID–19 Medical Production Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 9, 2021

Current Status: Referred to the House Committee on Financial Services.

Latest Action: Referred to the House Committee on Financial Services. (Mar 9, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/1720>

Sponsor

Name: Rep. Vargas, Juan [D-CA-51]

Party: Democratic • **State:** CA • **Chamber:** House

Cosponsors (1 total)

| Cosponsor | Party / State | Role | Date Joined |
|-------------------------------|---------------|------|-------------|
| Rep. Waters, Maxine [D-CA-43] | D · CA | | Mar 9, 2021 |

Committee Activity

| Committee | Chamber | Activity | Date |
|------------------------------|---------|-------------|-------------|
| Financial Services Committee | House | Referred To | Mar 9, 2021 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|-------------|--------------|--|
| 117 HR 1319 | Related bill | Mar 11, 2021: Became Public Law No: 117-2. |

Summary (as of Mar 9, 2021)

COVID-19 Medical Production Act

This bill provides additional funding for FY2021 to acquire medical supplies, vaccines, and other equipment to combat COVID-19 (i.e., coronavirus disease 2019) using authorities under the Defense Production Act of 1950. That act confers on the President a broad set of authorities to influence domestic industry to provide essential materials and goods for the national defense.

This funding is available through FY2025. Beginning in FY2023, it may be used to meet public health needs to address any pathogen determined by the President to have the potential to create a public health emergency.

Actions Timeline

- **Mar 9, 2021:** Introduced in House
- **Mar 9, 2021:** Referred to the House Committee on Financial Services.